David Jules Drutz

6372249, Apr 16, 2002

Oct 24, 1994

08/327874

James R. Smith - Houston TX
David J. Drutz - Houston TX
Deborah R. Wilson - Houston TX
Louis A. Zumstein - Houston TX

Baylor College of Medicine - Houston TX

A61K 9127

424450, 514 2, 514 12, 530350

The use of liposomal formulations, particularly formulations of positively charged and neutral lipids facilitates cellular uptake of SDI molecules. The transcription and/or expression of SDI-1-encoding nucleic acid molecules is facilitated by constructs that contain intervening untranslated regions.

6420347, Jul 16, 2002

Jul 17, 1998

09/101840

Karla M. Jacobus - Cary NC
Benjamin R. Yerxa - Raleigh NC
William Pendergast - Durham NC
Janet L. Rideout - Raleigh NC
David J. Drutz - Chapel Hill NC
Michael K. James - Raleigh NC
Monroe Jackson Stutts - Chapel Hill NC
Cary Geary - Seattle WA
Edwardo R. Lazarowski - Chapel Hill NC

Inspire Pharmaceuticals, Inc. - Durham NC
The University of North Carolina at Chapel Hill - Chapel Hill NC

A61K 3170

514 51, 514 48, 514 47

A method of stimulating ciliary beat frequency in a subject in need of such treatment is disclosed. The method comprises administering to the airways, ears, eyes, or genito-urinary tract of the subject a triphosphate nucleotide such as uridine 5â-triphosphate (UTP), an analog of UTP, or any other analog, in an amount effective to stimulate ciliary beat frequency. This method is useful for treating patients afflicted with ciliary dyskinesia, Kartageners syndrome, or any other disease involving dysfunction of ciliary movement, such as male infertility caused by impairment of propulsion of the spermatozoa or immune deficiency caused by impairment of ciliary movement in neutrophils or macrophages. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the same would include any liquid suspension (including nasal spray or nasal or eye drops), oral, inhaled by nebulization, topical, injected, suppository, intra-operative by instillation or application, or ex vivo direct application to spermatozoa.

6423694, Jul 23, 2002

Feb 21, 1996

08/604463

David J. Drutz - Houston TX
Janet L. Rideout - Raleigh NC
Karla M. Jacobus - Cary NC

Inspire Pharmaceuticals, Inc. - Durham NC

A61K 3170

514 51, 514 47, 424437, 424465

A method of promoting drainage of congested middle ear fluid in a subject in need of such treatment is disclosed. The method comprises administering to the middle ear of the subject a uridine triphosphate such as uridine 5â-triphosphate (UTP), an analog of UTP, or any other analog, in an amount effective to promote drainage of congested middle ear fluid by hydrating mucous secretions in the middle ear or by stimulating ciliary beat frequency in the middle ear or eustachian tube. The method is useful for treating patients afflicted with otitis media and other middle ear diseases, otitis externa, and inner ear diseases including MÃniÃres Disease. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the same would include any liquid suspension (including nasal drops or spray), oral, inhaled by nebulization, topical, injected or suppository form.

6673779, Jan 6, 2004

Jun 5, 2002

10/163804

Karla M. Jacobus - Cary NC
Benjamin R. Yerxa - Raleigh NC
William Pendergast - Durham NC
Janet L. Rideout - Raleigh NC
David J. Drutz - Chapel Hill NC
Michael K. James - Raleigh NC
Monroe Jackson Stutts - Chapel Hill NC
Cara Geary - Cincinnati OH
Eduardo R. Lazarowski - Durham NC

Inspire Pharmaceuticals, Inc. - Durham NC
The University of North Carolina at Chapel Hill - Chapel Hill NC

A61K 3170

514 51, 536 2621

The present invention is directed to a method of stimulating ciliary beat frequency to promote mucociliary or cough clearance of retained mucus secretions from the lungs, sinuses, upper airways, ears, eyes, genito-urinary tract, spermatozoa, ovaries, fallopian tubes, neutrophils, and macrophages of a patient. The method comprises administering uridine triphosphates, adenosine triphosphates, cytidine triphosphates, or dinucleoside tetraphosphates and the derivatives thereof to an affected body of a patient, to treat dysfunction of the mucociliary clearance system as a result of impaired ciliary movement in the patient.

20050089933, Apr 28, 2005

Aug 5, 2004

10/912448

Stephen Friedman - Chapel Hill NC, US
David Drutz - Chapel Hill NC, US

Syntherica Corporation - Durham NC

C12Q001/68
G01N033/53
C07K016/44

435007100, 530387300, 435006000

Methods and compositions for the modulation of an immune response are provided. Compositions comprise a bi-functional surrogate antibody molecule that interacts with a ligand of interest, wherein the bi-functional surrogate antibody further has attached thereto an immunomodulatory agent and/or a transporting agent. The compositions of the invention find use in a method for delivering an immunomodulatory agent to a ligand of interest. Further provided are methods for modulating an immune response in a subject against a ligand of interest. The method comprises administering a therapeutically effective amount of a bi-functional surrogate antibody of the invention. The methods of the invention also find use in improving the clinical outcome of a subject in need of a modulation in the immune response. Methods are further provided for the treatment or prevention of a variety of conditions and/or disorders including cancer, autoimmune diseases, allergies, prions, and various diseases or conditions of bacterial, parasitic, yeast or viral etiology.

20080194672, Aug 14, 2008

Feb 8, 2008

12/028611

Hamid Hoveyda - Quebec, CA
Graeme L. Fraser - Rixensart, BE
Kamel Benakli - Skippack PA, US
Sophie Beauchemin - Quebec, CA
Martin Brassard - Quebec, CA
David Drutz - Chapel Hill NC, US
Eric Marsault - Quebec, CA
Luc Ouellet - Quebec, CA
Mark L. Peterson - Sherbrooke, CA
Zhigang Wang - Quebec, CA

A61K 31/395
C07D 267/00
A61P 3/00
A61P 9/00
A61P 25/00
A61P 35/04
A61P 19/00
A61P 29/00
A61P 1/00
A61P 5/00
C07C 43/205

514450, 540455, 568584

The present invention provides novel conformationally-defined macrocyclic compounds that can function as selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, bone disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.

20110105389, May 5, 2011

Oct 29, 2010

12/916205

Hamid R. Hoveyda - Bruxelles, BE
Eric Marsault - Quebec, CA
Helmut Thomas - Quebec, CA
Graeme Fraser - Rixensart, BE
Sylvie Beaubien - Quebec, CA
Axel Mathieu - Quebec, CA
Julien Beignet - Quebec, CA
Marc-André Bonin - Quebec, CA
Serge Phoenix - Quebec, CA
David Drutz - Chapel Hill NC, US
Mark Peterson - Quebec, CA
Sophie Beauchemin - Quebec, CA
Martin Brassard - Quebec, CA
Martin Vezina - Quebec, CA

A61K 38/12
C07K 5/08
C07K 5/087
A61K 38/26
A61P 3/04
A61P 3/10
A61P 25/00
A61P 25/32
A61P 9/00
A61P 1/00
A61P 3/00
A61P 1/16
A61P 5/00
A61P 25/30

514 48, 530331, 514 211, 514 117, 514 69, 514 175, 514 177

The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (GRLN, growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and/or variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as antagonists or inverse agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, obesity and obesity-associated disorders, appetite or eating disorders, addictive disorders, cardiovascular disorders, gastrointestinal disorders, genetic disorders, hyperproliferative disorders, central nervous system disorders and inflammatory disorders.

59588977, Sep 28, 1999

Jan 9, 1998

9/004784

Karla Jacobus - Cary NC
Janet Rideout - Raleigh NC
Ben Yerxa - Raleigh NC
William Pendergast - Durham NC
Suhaib Siddiqi - Raleigh NC
David Drutz - Houston TX

Inspire Pharmaceuticals, Inc. - Durham NC

A61K 3170

514 49

A method of promoting drainage of congested mucous secretions in the sinuses of a subject in need of such treatment is disclosed. The method comprises administering to the sinuses of the subject a uridine phosphate such as uridine 5'-triphosphate (UTP) or P. sup. 1,P. sup. 4 -di(uridine-5') tetraphosphate (U. sub. 2 P. sub. 4), an analog of UTP, or any other analog, in an amount effective to promote drainage of congested fluid in the sinuses by hydrating mucous secretions or by stimulating ciliary beat frequency in the sinuses. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the same would include any liquid suspension (including nasal drops or spray), oral form (liquid or pill), aerosol inhalation, powder form, topical, injected, intra-operative instillation or suppository form.